Clinical Trial Update: CYP2C19 Genotype Predictor of Gastric Acid Suppression [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating a CYP2C19 genotype predictor for gastric acid suppression has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagitis

Snippet

Sponsor: Mayo Clinic | Conditions: Esophagitis | EARLY_Phase 1 | Status: WITHDRAWN